Related Content


Pathway to Counterfeiting

June 26, 2009

McGuireWoods presented a complimentary webinar on diversion—the sale of products outside authorized distribution channels.

Pharmaceutical and medical device diversion is on the rise, and has become a multibillion-dollar enterprise. However, diversion's economic side effects pale in comparison to the serious impact on the public health—as diverters sell outdated or adulterated product, and as counterfeiters use gray market channels to sell their counterfeit product. This session examines the increased economic and health risks posed by the diversion/gray market sales of pharmaceutical and medical device products. Our panel discusses how diversion happens; how to prevent, detect, investigate, and deter it; and how to recoup losses with courthouse strategies that are consistent with an anti-diversion scheme.


Kathleen Dooley, Partner, McGuireWoods LLP
Shirell A. Gross, Senior Counsel, Bayer HealthCare Diabetes Care
Jonathan Vogel, Partner, McGuireWoods LLP
Matthew Hoefling, Partner, McGuireWoods LLP

Media downloads: